Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01726582 · ClinicalTrials.gov registry record · Phase 2
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 229
- Enrollment target
NCT01726582 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 229 participants.
The verdict
NCT01726582, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 229 participants
- Enrollment target
Study Summary
In this clinical trial, if the doctor knows or suspects that a growth in the pancreas is cancer (adenocarcinoma), then a sample of the growth is tested (the test is called molecular profiling). The results of the test are used by the doctor to recommend therapy (chemotherapy and radiation therapy) that the patient will receive before having surgery to remove the adenocarcinoma. When the patient goes to surgery, the adenocarcinoma that is removed is tested again. The results of that test are used to guide the choice of therapy after surgery. The chemotherapy drugs and the radiation therapy used in this clinical trial are already approved for treatment of pancreas cancer. This trial is intended to establish which treatment is best for a specific patient, based on test results from that patient's actual adenocarcinoma. In the past, the decision as to which treatment the patient will receive was not based on testing of the actual adenocarcinoma. See treatment pathways at http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm. Hypothesis: Resectability rate, overall survival rate and progression-free survival in subjects with adenocarcinoma of the pancreas will be superior for who receive targeted "personalized" therapy.
Interventions
- DRUG Milestone 1: Targeted chemotherapy prior to surgery
- RADIATION Milestone 2: Chemoradiotherapy (cXRT)
- DRUG Milestone 3: Targeted chemotherapy prior to surgery
- RADIATION Milestone 3: Chemoradiotherapy (cXRT)
- DRUG Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2011-11 |
| Est. Completion | 2022-04-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01726582
The ClinicalTrials.gov registry entry for NCT01726582 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Milestone 1: Targeted chemotherapy prior to surgery is the first listed.
NCT01726582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01726582 about?
NCT01726582 is a clinical study titled "Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")". In this clinical trial, if the doctor knows or suspects that a growth in the pancreas is cancer (adenocarcinoma), then a sample of the growth is tested (the test is called molecular profiling). The results of the test are used by the doctor to recommend therapy (chemotherapy and radiation therapy) t...
What is the current status of trial NCT01726582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 229 participants. The study started on 2011-11. Estimated completion is 2022-04-11.
What interventions are being tested in trial NCT01726582?
The interventions under investigation include: Milestone 1: Targeted chemotherapy prior to surgery (DRUG), Milestone 2: Chemoradiotherapy (cXRT) (RADIATION), Milestone 3: Targeted chemotherapy prior to surgery (DRUG), Milestone 3: Chemoradiotherapy (cXRT) (RADIATION), Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery (DRUG).
Who is sponsoring clinical trial NCT01726582?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.